L&C BIO said on the 3rd that it registered a U.S. patent for the bone regeneration graft "MegaDBM® S."
The patent is for a "composite demineralized bone composition containing bone mineral components and its manufacturing process," marking the company's 29th registered patent and, in the United States, its third after the human-derived skin regeneration material "MegaDerm" and the tissue-regenerating functional peptide "ZAG peptide."
MegaDBM S is a bone regeneration graft based on demineralized bone matrix (DBM) derived from human bone and bone mineral components. It is designed to replace bone defects while enabling both osteoinduction and osteoconduction.
The core of this patent is a manufacturing technology that can obtain demineralized bone and bone minerals simultaneously through a one-step process. The company said this enables a mineral composition similar to human bone and provides an environment necessary for bone formation.
The product was developed in a semi-solid (paste) form to improve ease of application at the treatment site and shape retention, and it applies a biocompatible polymer so it can be stably fixed to the bone defect area.
L&C BIO previously secured domestic and Chinese patents related to MegaDBM S, and with this U.S. patent registration, it has expanded the global intellectual property protection system for its core regenerative medicine product line.
Lee Hwan-cheol of L&C BIO said, "This U.S. patent registration lays the groundwork for the company's human tissue processing and manufacturing technologies and regenerative material design capabilities to be protected in the global market," adding, "We will continue to push for global business expansion in regenerative medicine for the musculoskeletal system, including orthopedics and spine."